Anvisa Approves New Medicine to Treat Lupus
8 Articles
8 Articles
The medicine obinutuzumab (trade name Gazya) was approved by the National Agency for Health Surveillance (Anvisa) for systemic lupus erythematosus. According to the autarchy, it is indicated in the treatment of adult patients in moderate to severe active cases, positive for autoantibodies and in use of standard treatment. Small large dogs X: why one group lives less than the other? New study explains Netinho: understand what non-Hodgkin lymphoma…
Brasilia, Oct 14 (Latin Press) The Brazilian National Health Surveillance Agency authorized a new indication of obinutuzumab for adults with moderate to severe active systemic lupus erythematosus, reported today the regulatory entity. The post Amplifies in Brazil treatment for lupus in adults first appeared on Noticias Prensa Latina.
Gazyva drug may treat adults with moderate to severe lupus; therapy reduces seizures and the need for corticosteroids. Read on Power360.
The National Agency for Health Surveillance (Anvisa) approved the use of the medicine Gazyva (obinutuzumab) in the treatment of adults with moderate to severe active lupus. The indication is valid for patients with positive autoantibodies who already do standard treatment for the disease. The medicine was already used in some cases of cancer. According to Anvisa, obinutuzumab [...] The post Anvisa wide use of medicine to treat lupus in adults ap…
Gazyva can be used to treat lupus in adult patients with the disease considered moderate or severe Post Anvisa frees for patients with lupus medicine that treats cancer apareceu primeiro em AMAZONAS CURRENT.
Tribuna Online
The medicine Gazyva (obinutuzumab), indicated for some cancer cases, can be used from now on in the treatment of lupus. The National Agency for Health Surveillance (Anvisa) began to recommend the substance for adult patients with moderate to severe active lupus, positive for autoantibodies, using standard treatment.In a note, Anvisa reported that obinutuzumab is a humanized monoclonal antibody that promotes massive and prolonged elimination of B…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
